Amphotericin B: Brand change
The funded brand of amphotericin B liposomal injection 50 mg is changing from Gilead to Boucher and Muir.
What's changing?
Boucher and Muir was awarded the tender for amphotericin B liposomal injection - 50 mg in August 2025. Its product was listed from 1 November 2025.
| Description | New product | Current product |
|---|---|---|
| Brand as listed in the Schedule | Boucher and Muir | Gilead |
| Label | Amphotericin Liposomal SUN | AmBisome |
| Presentation | B inj liposomal 50 mg vial | B inj liposomal 50 mg vial |
| Pharmacode | 2714264 | 231495, 2229323 |
| Quantity | 1 vial packs | 1 and 10 vial packs |
| Shelf life | 24 months | 48 months |
| Instructions after reconstitution | 24 hours (stored at 2° to 8°C, refrigerate, do not freeze). | 72 hours (stored at 2° to 8°C, refrigerate, do not freeze). |
- Amphotericin B Brand Change [PDF 118 KB]
Key dates
1 November 2025 | Boucher and Muir brand of amphotericin B injection 50 mg listed.
1 April 2026 | Gilead brand of amphotericin B injection 50 mg will be delisted.
1 April 2026 | Principal Supply Status (PSS) for Boucher and Muir brand of amphotericin B injection 50 mg starts.
Who to contact
If you have questions about this issue, email enquiry@pharmac.govt.nz
Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.
Sign up to our email list for regular emails about supply issues and more(external link)
Pharmac is a government agency. We do not sell medicines or related products.